CD4 and metabolic dysfunction-associated steatotic liver disease: Another study showed that bone marrow-derived MSCs could attenuate hepatic steatosis, inflammation and fibrosis in NAFLD model mice by suppressing the activation capacity of CD4 + T cells [496].